Paper
Organic & Biomolecular Chemistry
C-5), 53.4 (CH2), 84.7 (C-6a), 117.6, 124.4 (CH), 124.8 (CH),
125.0 (CH), 127.5 (q, JC,F = 286.6 Hz, CF3), 128.2 (CH), 128.8,
2 M. Palmer, J. F. Honek and T. Dieckmann, Biochemical
Pharmacology, John Wiley & Sons, 1st edn, 2012, p. 428,
ISBN-13: 978-0-470-17445-6.
3 J.-P. Begue and D. Bonnet-Delpont, Bioorganic and Medic-
inal Chemistry of Fluorine, John Wiley & Sons, 1st edn, 2008,
p. 366, ISBN-10: 0470278307.
4 (a) A. Ohno, J. Kunitomo, Y. Kawai, T. Kawamoto,
M. Tomishima and F. Yoneda, J. Org. Chem., 1996, 61,
9344–9355; (b) F. Yoneda, K. Mori, Y. Sakuma and
H. Yamaguchi, J. Chem. Soc., Perkin Trans. 1, 1980, 978–
981; (c) T. Nagamatsu, Y. Hashiguchi, M. Higuchi and
F. Yoneda, J. Chem. Soc., Chem. Commun., 1982, 1085–1086;
(d) K. Mori, K. Shinozuka, Y. Sakuma and F. Yoneda,
J. Chem. Soc., Chem. Commun., 1978, 764.
1
128.9 (CH), 133.3, 137.2, 141.8, 152.9, 152.9, 162.0, 195.7; 19F
NMR (235.3 MHz, CDCl3): δ = −76.8 (s, CF3); MS (GC, 70 eV):
m/z (%) = 455 ([M]+, 5.8), 387 (26), 386 (100), 336 (15), 105 (38),
77 (14); HRMS (ESI): calcd for C24H21F3N3O3 [M + H]+:
456.15295, found: 456.15399; IR (ATR, cm−1): ν = 3043 (w),
3016 (w), 2929 (w), 1691 (s), 1633 (s), 1626 (s), 1539 (s),
1498 (s), 1464 (s), 1446 (s), 1435 (s), 1408 (s), 1375 (s), 1360 (s),
1342 (m), 1302 (m), 1242 (s), 1227 (s), 1201 (m), 1186 (m),
1176 (m), 1155 (s), 1120 (s), 1078 (m), 1057 (m), 1041 (m),
1028 (m), 1001 (m), 976 (m), 964 (m), 939 (m), 912 (m),
897 (w), 860 (w), 847 (w), 779 (s), 770 (m), 756 (s), 748 (s), 737 (s),
714 (m), 694 (s), 658 (m), 617 (s), 581 (m), 569 (m), 528 (m).
5 F. Yoneda and Y. Sakuma, J. Chem. Soc., Chem. Commun.,
1977, 825–826.
Addition of hydrogen cyanide to 1,3-dimethyl-5-
(trifluoromethyl)pyrimido[4,5-b]quinoline-2,4-diones 4f and
7a. Synthesis of compounds 12c and 13c
6 (a) H.-J. Duchstein, H. Fenner, P. Frank and W. Bauch,
Arch. Pharm., 1990, 323, 67–72; (b) H.-J. Duchstein,
H. Fenner and W. Bauch, Arch. Pharm., 1989, 322, 271–275.
7 (a) J. T. Welch, Tetrahedron, 1987, 43, 3123–3197; (b) P. Lin
and J. Jiang, Tetrahedron, 2000, 56, 3635–3671;
(c) G. Resnati, Tetrahedron, 1993, 49, 9385–9445.
Compound 4f or 7a (1 equiv.) was suspended in DMSO and
KCN (2 equiv.) was added. Then the reaction mixture was
stirred overnight and acetic acid (2 equiv.) was carefully added
under a fume hood. Afterwards the mixture was diluted with
water and the formed precipitate was filtered off by suction
and recrystallized from methanol–water giving the pure
product.
8 T. Hiyama, Organofluorine Compounds: Chemistry and Appli-
cation, Springer, Berlin, 2000.
9 (a) V. O. Iaroshenko, D. V. Sevenard, A. V. Kotljarov,
D. M. Volochnyuk, A. O. Tolmachev and V. Y. Sosnovskikh,
Synthesis, 2009, 731–740; (b) V. O. Iaroshenko, Synthesis,
2009, 3967–3974; (c) V. O. Iaroshenko, D. Ostrovskyi,
A. Petrosyan, S. Mkrtchyan, A. Villinger and P. Langer,
J. Org. Chem., 2011, 76, 2899–2903.
10 (a) G. Cristalli, S. Costanzi, C. Lambertucci, G. Lupidi,
S. Vittori, R. Volpini and E. Camaioni, Med. Res. Rev., 2001,
21, 105–128; (b) O. Maydanovych and P. A. Beal, Chem. Rev.,
2006, 106, 3397–3411; (c) E. Santaniello, P. Ciuffreda and
L. Alessandrini, Synthesis, 2005, 509–526.
7-Ethyl-1,3-dimethyl-2,4-dioxo-5-(trifluoromethyl)-1,2,3,4,5,10-
hexahydropyrimido[4,5-b]quinoline-5-carbonitrile (12c). Yield
1
94%, white solid, mp 179 °C. H NMR (300.1 MHz, DMSO-d6):
3
3
δ = 1.22 (t, 3H, J = 7.6 Hz, Me), 2.70 (q, 2H, J = 7.6 Hz, CH2),
3.26 (s, 3H, Me), 3.54 (s, 3H, Me), 7.43 (dd, 1H, 3J = 8.4 Hz, 4J =
3
1.8 Hz, H-8), 7.51 (d, 1H, J = 8.4 Hz, H-9), 7.53 (s, 1H, H-6),
9.96 (br s, 1H, NH); 13C NMR (75.5 MHz, DMSO-d6): δ = 16.4
2
(Me), 28.3 (CH2), 28.8 (Me), 31.4 (Me), 46.3 (q, JC,F = 31.9 Hz,
C-5), 74.5 (C-4a), 112.6, 115.9, 118.7 (CH), 124.8 (q, JC,F
1
=
289.3 Hz, CF3), 128.4 (CH), 131.7 (CH), 134.6, 141.0, 148.3,
151.0, 160.4; 19F NMR (282.4 MHz, DMSO-d6): δ = −75.1 (s,
CF3); MS (EI, 70 eV): m/z (%) = 364 ([M]+, 1.03), 338 (17), 337
([M − HCN]+, 97), 322 (27), 309 (11), 296 (10), 295 (53), 280 (11),
268 (19), 265 (23), 239 (10), 238 (16), 237 (11), 226 (12),
225 (100), 224 (13), 210 (17), 196 (11); HRMS (ESI): calcd for
C17H16F3N4O2 [M + H]+: 365.12199, found: 365.12186; IR (ATR,
cm−1): ν = 3526 (w), 3326 (m), 2977 (w), 1688 (m), 1633 (m),
1613 (s), 1601 (m), 1531 (s), 1502 (s), 1472 (s), 1435 (s),
1414 (m), 1392 (w), 1368 (w), 1338 (w), 1300 (w), 1260 (w),
1232 (w), 1218 (m), 1180 (s), 1159 (m), 1145 (m), 1101 (w),
1068 (w), 1035 (m), 1002 (w), 965 (m), 940 (w), 894 (w), 866 (w),
835 (s), 771 (m), 759 (m), 733 (w), 706 (w), 692 (w), 661 (w),
577 (m), 565 (m), 545 (m), 531 (w).
11 (a) G. Cristalli, S. Costanzi, C. Lambertucci, G. Lupidi,
S. Vittori, R. Volpini and E. Camaioni, Med. Res. Rev., 2001,
21, 105–128; (b) V. Nair, IMPDH Inhibitors: Discovery of Anti-
viral Agents Against Emerging Diseases in Antiviral Drug
Discovery for Emerging Diseases and Bioterrorism Threats, ed.
P. F. Torrence, John Wiley & Sons, Inc., Hoboken, 2005, ch.
8, pp. 179–202; (c) Q. Shu and V. Nair, Med. Res. Rev., 2008,
219–232; (d) M. D. Erion and M. R. Reddy, J. Am. Chem.
Soc., 1998, 120, 3295–3307; (e) L. Hedstrom, Chem. Rev.,
2009, 109, 2903–2928.
12 (a) K. Senga, F. Yoneda and S. Nishigaki, J. Org. Chem.,
1971, 36, 1829–1831; (b) S. Wawzonek, J. Org. Chem., 1976,
41, 3149–3151; (c) F. Yoneda, F. Takayama and A. Koshiro,
Chem. Pharm. Bull., 1979, 27, 2507–2510; (d) K. Hirota,
K. Kubo, H. Sajiki, Y. Kitade, M. Sako and Y. Maki, J. Org.
Chem., 1997, 62, 2999–3001; (e) A. Chandra, S. Upadhyay,
B. Singh, N. Sharma and R. M. Singh, Tetrahedron, 2011,
67, 9219–9224.
Notes and references
1 R. B. Silverman, The Organic Chemistry of Drug Design, and 13 Z. Wang and C. J. Rizzo, Org. Lett., 2000, 2, 227–230.
Drug Action, Elsevier Academic Press, 2nd edn, 2004, 14 (a) F. Yoneda, Y. Sakuma, S. Mizumoto and R. Ito, J. Chem.
p. 617, ISBN 0-12-643732-7.
Soc., Perkin Trans. 1, 1976, 1805–1808; (b) P. A. J. Link,
Org. Biomol. Chem.
This journal is © The Royal Society of Chemistry 2013